EDIT
Price
$7.42
Change
-$0.02 (-0.27%)
Updated
Mar 28, 6:59 PM EST
33 days until earnings call
NKTR
Price
$0.93
Change
+$0.04 (+4.49%)
Updated
Mar 28, 6:59 PM EST
40 days until earnings call
Ad is loading...

Compare trend and price EDIT vs NKTR

Header iconEDIT vs NKTR Comparison
Open Charts EDIT vs NKTRBanner chart's image
Editas Medicine
Price$7.42
Change-$0.02 (-0.27%)
Volume$954.97K
CapitalizationN/A
Nektar Therapeutics
Price$0.93
Change+$0.04 (+4.49%)
Volume$834.64K
CapitalizationN/A
View a ticker or compare two or three
EDIT vs NKTR Comparison Chart

Loading...

EDITDaily Signal changed days agoGain/Loss if shorted
 
Show more...
NKTRDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
EDIT vs. NKTR commentary
Mar 29, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and NKTR is a StrongBuy.

COMPARISON
Comparison
Mar 29, 2024
Stock price -- (EDIT: $7.42 vs. NKTR: $0.94)
Brand notoriety: EDIT: Not notable vs. NKTR: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 83% vs. NKTR: 68%
Market capitalization -- EDIT: $607.06M vs. NKTR: $172.6M
EDIT [@Biotechnology] is valued at $607.06M. NKTR’s [@Biotechnology] market capitalization is $172.6M. The market cap for tickers in the [@Biotechnology] industry ranges from $570.99B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 1 FA rating(s) are green whileNKTR’s FA Score has 0 green FA rating(s).

  • EDIT’s FA Score: 1 green, 4 red.
  • NKTR’s FA Score: 0 green, 5 red.
According to our system of comparison, both EDIT and NKTR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 2 TA indicator(s) are bullish while NKTR’s TA Score has 4 bullish TA indicator(s).

  • EDIT’s TA Score: 2 bullish, 9 bearish.
  • NKTR’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, NKTR is a better buy in the short-term than EDIT.

Price Growth

EDIT (@Biotechnology) experienced а -5.24% price change this week, while NKTR (@Biotechnology) price change was +4.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.98%. For the same industry, the average monthly price growth was +8.91%, and the average quarterly price growth was +90.55%.

Reported Earning Dates

EDIT is expected to report earnings on May 01, 2024.

NKTR is expected to report earnings on May 08, 2024.

Industries' Descriptions

@Biotechnology (+4.98% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for EDIT with price predictions.
OPEN
A.I.dvisor published
a Summary for NKTR with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
EDIT($607M) has a higher market cap than NKTR($173M). NKTR YTD gains are higher at: 66.372 vs. EDIT (-26.752). EDIT has higher annual earnings (EBITDA): -163.12M vs. NKTR (-243.11M). EDIT has more cash in the bank: 323M vs. NKTR (304M). EDIT has less debt than NKTR: EDIT (36.5M) vs NKTR (118M). NKTR has higher revenues than EDIT: NKTR (90.1M) vs EDIT (78.1M).
EDITNKTREDIT / NKTR
Capitalization607M173M351%
EBITDA-163.12M-243.11M67%
Gain YTD-26.75266.372-40%
P/E RatioN/AN/A-
Revenue78.1M90.1M87%
Total Cash323M304M106%
Total Debt36.5M118M31%
FUNDAMENTALS RATINGS
EDIT vs NKTR: Fundamental Ratings
EDIT
NKTR
OUTLOOK RATING
1..100
5720
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
53
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
6437
P/E GROWTH RATING
1..100
10085
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (27) in the Biotechnology industry is in the same range as NKTR (53). This means that EDIT’s stock grew similarly to NKTR’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NKTR (100). This means that EDIT’s stock grew similarly to NKTR’s over the last 12 months.

EDIT's SMR Rating (97) in the Biotechnology industry is in the same range as NKTR (98). This means that EDIT’s stock grew similarly to NKTR’s over the last 12 months.

NKTR's Price Growth Rating (37) in the Biotechnology industry is in the same range as EDIT (64). This means that NKTR’s stock grew similarly to EDIT’s over the last 12 months.

NKTR's P/E Growth Rating (85) in the Biotechnology industry is in the same range as EDIT (100). This means that NKTR’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITNKTR
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
74%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
73%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
72%
Advances
ODDS (%)
Bullish Trend 9 days ago
77%
Bullish Trend 8 days ago
75%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 18 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
63%
View a ticker or compare two or three
Ad is loading...
EDITDaily Signal changed days agoGain/Loss if shorted
 
Show more...
NKTRDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PNOTX22.170.05
+0.23%
Putnam Sustainable Future R6
TAMMX33.990.02
+0.06%
Transamerica Multi-Managed Balanced R6
TSWIX20.99N/A
N/A
Transamerica International Equity I
GSAOX15.20N/A
N/A
Goldman Sachs Small Cap Gr Insghts A
TVVIX11.73N/A
N/A
Guggenheim RBP® Large-Cap Value I